Werewolf Therapeutics’ stock is up 1,431.19% pre-market after announcing a definitive all-stock merger agreement with Ambros Therapeutics. The deal—being positioned as a major corporate development—appears to be driving an outsized immediate re-rating of HOWL shares.
Werewolf Therapeutics’ stock is up 1,431.19% pre-market after announcing a definitive all-stock merger agreement with Ambros Therapeutics. The deal—being positioned as a major corporate development—appears to be driving an outsized immediate re-rating of HOWL shares.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
